Vertex Pharmaceuticals Reports Real-World Outcomes for Trikafta in Cystic Fibrosis

Vertex Pharmaceuticals today presented real-world evidence from multiple registries and observational studies showing that Trikafta (elexacaftor/tezacaftor/ivacaftor) significantly improves lung function, reduces pulmonary exacerbations, and decreases hospitalizations in patients with cystic fibrosis in clinical practice. The real-world data are consistent with clinical trial results and demonstrate the transformative impact of Trikafta on the lives of people with CF.